Treatment of the symptoms of Huntington's disease: Preliminary results comparing aripiprazole and tetrabenazine
Identifieur interne : 002D82 ( Main/Corpus ); précédent : 002D81; suivant : 002D83Treatment of the symptoms of Huntington's disease: Preliminary results comparing aripiprazole and tetrabenazine
Auteurs : Livia Brusa ; Antonio Orlacchio ; Vincenzo Moschella ; Cesare Iani ; Giorgio Bernardi ; Nicola Biagio MercuriSource :
- Movement Disorders [ 0885-3185 ] ; 2009-01-15.
English descriptors
Abstract
Aripiprazole (AP), a dopamine (DA) D2 receptor partial agonist, has recently been used to reduce schizophrenic symptoms, while tetrabenazine (TBZ), a DA depletor, has been used to treat hyperkinesias in Huntington's disease (HD). The aim of this study is to define the role of AP on chorea, motor performance, and functional disability, and to compare the effects of AP vs. TBZ in a small study of six patients with HD. Both AP and TBZ increased the Unified Huntington's Disease Rating Scale (UHDRS) chorea score in a similar way. However, AP caused less sedation and sleepiness than TBZ and was better tolerated by the patients on the trial. Moreover, AP showed a slight but not significant improvement of depression in the patients as compared to TBZ. A larger group of patients and a longer period of observation are an important prerequisite for further evaluations of AP's therapeutic use. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.22376
Links to Exploration step
ISTEX:A4EAA2B1C46701DE647AB267806AF6E63F520792Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of the symptoms of Huntington's disease: Preliminary results comparing aripiprazole and tetrabenazine</title><author><name sortKey="Brusa, Livia" sort="Brusa, Livia" uniqKey="Brusa L" first="Livia" last="Brusa">Livia Brusa</name><affiliation><mods:affiliation>UOC Neurologia, Ospedale Sant'Eugenio, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Orlacchio, Antonio" sort="Orlacchio, Antonio" uniqKey="Orlacchio A" first="Antonio" last="Orlacchio">Antonio Orlacchio</name><affiliation><mods:affiliation>Laboratorio di Neurogenetica, CERC‐IRCCS Santa Lucia, Rome, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>Dipartimento di Neuroscienze, Università di Roma “Tor Vergata”, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Moschella, Vincenzo" sort="Moschella, Vincenzo" uniqKey="Moschella V" first="Vincenzo" last="Moschella">Vincenzo Moschella</name><affiliation><mods:affiliation>Dipartimento di Neuroscienze, Università di Roma “Tor Vergata”, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Iani, Cesare" sort="Iani, Cesare" uniqKey="Iani C" first="Cesare" last="Iani">Cesare Iani</name><affiliation><mods:affiliation>UOC Neurologia, Ospedale Sant'Eugenio, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Bernardi, Giorgio" sort="Bernardi, Giorgio" uniqKey="Bernardi G" first="Giorgio" last="Bernardi">Giorgio Bernardi</name><affiliation><mods:affiliation>Laboratorio di Neurogenetica, CERC‐IRCCS Santa Lucia, Rome, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>Dipartimento di Neuroscienze, Università di Roma “Tor Vergata”, Rome, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>Laboratorio di Neurologia Sperimentale, CERC‐IRCCS Santa Lucia, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Mercuri, Nicola Biagio" sort="Mercuri, Nicola Biagio" uniqKey="Mercuri N" first="Nicola Biagio" last="Mercuri">Nicola Biagio Mercuri</name><affiliation><mods:affiliation>Dipartimento di Neuroscienze, Università di Roma “Tor Vergata”, Rome, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>Laboratorio di Neurologia Sperimentale, CERC‐IRCCS Santa Lucia, Rome, Italy</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A4EAA2B1C46701DE647AB267806AF6E63F520792</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22376</idno><idno type="url">https://api.istex.fr/document/A4EAA2B1C46701DE647AB267806AF6E63F520792/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002D82</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Treatment of the symptoms of Huntington's disease: Preliminary results comparing aripiprazole and tetrabenazine</title><author><name sortKey="Brusa, Livia" sort="Brusa, Livia" uniqKey="Brusa L" first="Livia" last="Brusa">Livia Brusa</name><affiliation><mods:affiliation>UOC Neurologia, Ospedale Sant'Eugenio, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Orlacchio, Antonio" sort="Orlacchio, Antonio" uniqKey="Orlacchio A" first="Antonio" last="Orlacchio">Antonio Orlacchio</name><affiliation><mods:affiliation>Laboratorio di Neurogenetica, CERC‐IRCCS Santa Lucia, Rome, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>Dipartimento di Neuroscienze, Università di Roma “Tor Vergata”, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Moschella, Vincenzo" sort="Moschella, Vincenzo" uniqKey="Moschella V" first="Vincenzo" last="Moschella">Vincenzo Moschella</name><affiliation><mods:affiliation>Dipartimento di Neuroscienze, Università di Roma “Tor Vergata”, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Iani, Cesare" sort="Iani, Cesare" uniqKey="Iani C" first="Cesare" last="Iani">Cesare Iani</name><affiliation><mods:affiliation>UOC Neurologia, Ospedale Sant'Eugenio, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Bernardi, Giorgio" sort="Bernardi, Giorgio" uniqKey="Bernardi G" first="Giorgio" last="Bernardi">Giorgio Bernardi</name><affiliation><mods:affiliation>Laboratorio di Neurogenetica, CERC‐IRCCS Santa Lucia, Rome, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>Dipartimento di Neuroscienze, Università di Roma “Tor Vergata”, Rome, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>Laboratorio di Neurologia Sperimentale, CERC‐IRCCS Santa Lucia, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Mercuri, Nicola Biagio" sort="Mercuri, Nicola Biagio" uniqKey="Mercuri N" first="Nicola Biagio" last="Mercuri">Nicola Biagio Mercuri</name><affiliation><mods:affiliation>Dipartimento di Neuroscienze, Università di Roma “Tor Vergata”, Rome, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>Laboratorio di Neurologia Sperimentale, CERC‐IRCCS Santa Lucia, Rome, Italy</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-01-15">2009-01-15</date><biblScope unit="volume">24</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="126">126</biblScope><biblScope unit="page" to="129">129</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">A4EAA2B1C46701DE647AB267806AF6E63F520792</idno><idno type="DOI">10.1002/mds.22376</idno><idno type="ArticleID">MDS22376</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Huntington's disease</term><term>aripiprazole</term><term>neuroleptics</term><term>tetrabenazine</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Aripiprazole (AP), a dopamine (DA) D2 receptor partial agonist, has recently been used to reduce schizophrenic symptoms, while tetrabenazine (TBZ), a DA depletor, has been used to treat hyperkinesias in Huntington's disease (HD). The aim of this study is to define the role of AP on chorea, motor performance, and functional disability, and to compare the effects of AP vs. TBZ in a small study of six patients with HD. Both AP and TBZ increased the Unified Huntington's Disease Rating Scale (UHDRS) chorea score in a similar way. However, AP caused less sedation and sleepiness than TBZ and was better tolerated by the patients on the trial. Moreover, AP showed a slight but not significant improvement of depression in the patients as compared to TBZ. A larger group of patients and a longer period of observation are an important prerequisite for further evaluations of AP's therapeutic use. © 2008 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Livia Brusa MD</name><affiliations><json:string>UOC Neurologia, Ospedale Sant'Eugenio, Rome, Italy</json:string></affiliations></json:item><json:item><name>Antonio Orlacchio MD, PhD</name><affiliations><json:string>Laboratorio di Neurogenetica, CERC‐IRCCS Santa Lucia, Rome, Italy</json:string><json:string>Dipartimento di Neuroscienze, Università di Roma “Tor Vergata”, Rome, Italy</json:string></affiliations></json:item><json:item><name>Vincenzo Moschella MD</name><affiliations><json:string>Dipartimento di Neuroscienze, Università di Roma “Tor Vergata”, Rome, Italy</json:string></affiliations></json:item><json:item><name>Cesare Iani MD</name><affiliations><json:string>UOC Neurologia, Ospedale Sant'Eugenio, Rome, Italy</json:string></affiliations></json:item><json:item><name>Giorgio Bernardi MD</name><affiliations><json:string>Laboratorio di Neurogenetica, CERC‐IRCCS Santa Lucia, Rome, Italy</json:string><json:string>Dipartimento di Neuroscienze, Università di Roma “Tor Vergata”, Rome, Italy</json:string><json:string>Laboratorio di Neurologia Sperimentale, CERC‐IRCCS Santa Lucia, Rome, Italy</json:string></affiliations></json:item><json:item><name>Nicola Biagio Mercuri MD</name><affiliations><json:string>Dipartimento di Neuroscienze, Università di Roma “Tor Vergata”, Rome, Italy</json:string><json:string>Laboratorio di Neurologia Sperimentale, CERC‐IRCCS Santa Lucia, Rome, Italy</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Huntington's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>aripiprazole</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>tetrabenazine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>neuroleptics</value></json:item></subject><articleId><json:string>MDS22376</json:string></articleId><language><json:string>eng</json:string></language><abstract>Aripiprazole (AP), a dopamine (DA) D2 receptor partial agonist, has recently been used to reduce schizophrenic symptoms, while tetrabenazine (TBZ), a DA depletor, has been used to treat hyperkinesias in Huntington's disease (HD). The aim of this study is to define the role of AP on chorea, motor performance, and functional disability, and to compare the effects of AP vs. TBZ in a small study of six patients with HD. Both AP and TBZ increased the Unified Huntington's Disease Rating Scale (UHDRS) chorea score in a similar way. However, AP caused less sedation and sleepiness than TBZ and was better tolerated by the patients on the trial. Moreover, AP showed a slight but not significant improvement of depression in the patients as compared to TBZ. A larger group of patients and a longer period of observation are an important prerequisite for further evaluations of AP's therapeutic use. © 2008 Movement Disorder Society</abstract><qualityIndicators><score>6.824</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>4</keywordCount><abstractCharCount>927</abstractCharCount><pdfWordCount>18996</pdfWordCount><pdfCharCount>125960</pdfCharCount><pdfPageCount>34</pdfPageCount><abstractWordCount>152</abstractWordCount></qualityIndicators><title>Treatment of the symptoms of Huntington's disease: Preliminary results comparing aripiprazole and tetrabenazine</title><genre><json:string>article</json:string></genre><host><volume>24</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>4</total><last>129</last><first>126</first></pages><issn><json:string>0885-3185</json:string></issn><issue>1</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2009</publicationDate><copyrightDate>2009</copyrightDate><doi><json:string>10.1002/mds.22376</json:string></doi><id>A4EAA2B1C46701DE647AB267806AF6E63F520792</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/A4EAA2B1C46701DE647AB267806AF6E63F520792/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/A4EAA2B1C46701DE647AB267806AF6E63F520792/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/A4EAA2B1C46701DE647AB267806AF6E63F520792/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Treatment of the symptoms of Huntington's disease: Preliminary results comparing aripiprazole and tetrabenazine</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2009</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: None reported.</note><note>Italian Ministry of Health - No. EBRI1.O; No. PS05.11; No. PS05.21; No. REG.13M; No. RF06.70M;</note><note>Comitato Telethon Fondazione Onlus</note><note>Amministrazione Autonoma dei Monopoli di Stato (AAMS)</note><note>Italian city of Gubbio - No. GGP06209;</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Treatment of the symptoms of Huntington's disease: Preliminary results comparing aripiprazole and tetrabenazine</title><author><persName><forename type="first">Livia</forename><surname>Brusa</surname></persName><roleName type="degree">MD</roleName><note type="biography">Dr. Brusa and Dr. Orlacchio contributed equally to this work.</note><affiliation>Dr. Brusa and Dr. Orlacchio contributed equally to this work.</affiliation><affiliation>UOC Neurologia, Ospedale Sant'Eugenio, Rome, Italy</affiliation></author><author><persName><forename type="first">Antonio</forename><surname>Orlacchio</surname></persName><roleName type="degree">MD, PhD</roleName><note type="biography">Dr. Brusa and Dr. Orlacchio contributed equally to this work.</note><affiliation>Dr. Brusa and Dr. Orlacchio contributed equally to this work.</affiliation><note type="correspondence"><p>Correspondence: Laboratorio di Neurogenetica, Centro Europeo di Ricerca sul Cervello (CERC), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Santa Lucia, 64 Via del Fosso di Fiorano, Rome 00143, Italy</p></note><affiliation>Laboratorio di Neurogenetica, CERC‐IRCCS Santa Lucia, Rome, Italy</affiliation><affiliation>Dipartimento di Neuroscienze, Università di Roma “Tor Vergata”, Rome, Italy</affiliation></author><author><persName><forename type="first">Vincenzo</forename><surname>Moschella</surname></persName><roleName type="degree">MD</roleName><affiliation>Dipartimento di Neuroscienze, Università di Roma “Tor Vergata”, Rome, Italy</affiliation></author><author><persName><forename type="first">Cesare</forename><surname>Iani</surname></persName><roleName type="degree">MD</roleName><affiliation>UOC Neurologia, Ospedale Sant'Eugenio, Rome, Italy</affiliation></author><author><persName><forename type="first">Giorgio</forename><surname>Bernardi</surname></persName><roleName type="degree">MD</roleName><affiliation>Laboratorio di Neurogenetica, CERC‐IRCCS Santa Lucia, Rome, Italy</affiliation><affiliation>Dipartimento di Neuroscienze, Università di Roma “Tor Vergata”, Rome, Italy</affiliation><affiliation>Laboratorio di Neurologia Sperimentale, CERC‐IRCCS Santa Lucia, Rome, Italy</affiliation></author><author><persName><forename type="first">Nicola Biagio</forename><surname>Mercuri</surname></persName><roleName type="degree">MD</roleName><affiliation>Dipartimento di Neuroscienze, Università di Roma “Tor Vergata”, Rome, Italy</affiliation><affiliation>Laboratorio di Neurologia Sperimentale, CERC‐IRCCS Santa Lucia, Rome, Italy</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-01-15"></date><biblScope unit="volume">24</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="126">126</biblScope><biblScope unit="page" to="129">129</biblScope></imprint></monogr><idno type="istex">A4EAA2B1C46701DE647AB267806AF6E63F520792</idno><idno type="DOI">10.1002/mds.22376</idno><idno type="ArticleID">MDS22376</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2009</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Aripiprazole (AP), a dopamine (DA) D2 receptor partial agonist, has recently been used to reduce schizophrenic symptoms, while tetrabenazine (TBZ), a DA depletor, has been used to treat hyperkinesias in Huntington's disease (HD). The aim of this study is to define the role of AP on chorea, motor performance, and functional disability, and to compare the effects of AP vs. TBZ in a small study of six patients with HD. Both AP and TBZ increased the Unified Huntington's Disease Rating Scale (UHDRS) chorea score in a similar way. However, AP caused less sedation and sleepiness than TBZ and was better tolerated by the patients on the trial. Moreover, AP showed a slight but not significant improvement of depression in the patients as compared to TBZ. A larger group of patients and a longer period of observation are an important prerequisite for further evaluations of AP's therapeutic use. © 2008 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Huntington's disease</term></item><item><term>aripiprazole</term></item><item><term>tetrabenazine</term></item><item><term>neuroleptics</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2008-04-20">Received</change><change when="2008-10-09">Registration</change><change when="2009-01-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/A4EAA2B1C46701DE647AB267806AF6E63F520792/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="10"><doi origin="wiley" registered="yes">10.1002/mds.v24:1</doi><numberingGroup><numbering type="journalVolume" number="24">24</numbering><numbering type="journalIssue">1</numbering></numberingGroup><coverDate startDate="2009-01-15">15 January 2009</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="200" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22376</doi><idGroup><id type="unit" value="MDS22376"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2008 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2008-04-20"></event><event type="manuscriptRevised" date="2008-10-06"></event><event type="manuscriptAccepted" date="2008-10-09"></event><event type="firstOnline" date="2008-11-17"></event><event type="publishedOnlineFinalForm" date="2009-01-23"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2008-11-17"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">126</numbering><numbering type="pageLast">129</numbering></numberingGroup><correspondenceTo>Laboratorio di Neurogenetica, Centro Europeo di Ricerca sul Cervello (CERC), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Santa Lucia, 64 Via del Fosso di Fiorano, Rome 00143, Italy</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22376.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="15"></count><count type="wordTotal" number="2131"></count></countGroup><titleGroup><title type="main" xml:lang="en">Treatment of the symptoms of Huntington's disease: Preliminary results comparing aripiprazole and tetrabenazine<link href="#fn3"></link></title><title type="short" xml:lang="en">Treatment of HD with AP or TBZ</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" noteRef="#fn5"><personName><givenNames>Livia</givenNames><familyName>Brusa</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2 #af3" corresponding="yes" noteRef="#fn5"><personName><givenNames>Antonio</givenNames><familyName>Orlacchio</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>a.orlacchio@hsantalucia.it</email></contactDetails></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Vincenzo</givenNames><familyName>Moschella</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Cesare</givenNames><familyName>Iani</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af2 #af3 #af4"><personName><givenNames>Giorgio</givenNames><familyName>Bernardi</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af3 #af4"><personName><givenNames>Nicola Biagio</givenNames><familyName>Mercuri</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="IT" type="organization"><unparsedAffiliation>UOC Neurologia, Ospedale Sant'Eugenio, Rome, Italy</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="IT" type="organization"><unparsedAffiliation>Laboratorio di Neurogenetica, CERC‐IRCCS Santa Lucia, Rome, Italy</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="IT" type="organization"><unparsedAffiliation>Dipartimento di Neuroscienze, Università di Roma “Tor Vergata”, Rome, Italy</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="IT" type="organization"><unparsedAffiliation>Laboratorio di Neurologia Sperimentale, CERC‐IRCCS Santa Lucia, Rome, Italy</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Huntington's disease</keyword><keyword xml:id="kwd2">aripiprazole</keyword><keyword xml:id="kwd3">tetrabenazine</keyword><keyword xml:id="kwd4">neuroleptics</keyword></keywordGroup><fundingInfo><fundingAgency>Italian Ministry of Health</fundingAgency><fundingNumber>EBRI1.O</fundingNumber><fundingNumber>PS05.11</fundingNumber><fundingNumber>PS05.21</fundingNumber><fundingNumber>REG.13M</fundingNumber><fundingNumber>RF06.70M</fundingNumber></fundingInfo><fundingInfo><fundingAgency>Comitato Telethon Fondazione Onlus</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Amministrazione Autonoma dei Monopoli di Stato (AAMS)</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Italian city of Gubbio</fundingAgency><fundingNumber>GGP06209</fundingNumber></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Aripiprazole (AP), a dopamine (DA) D<sub>2</sub> receptor partial agonist, has recently been used to reduce schizophrenic symptoms, while tetrabenazine (TBZ), a DA depletor, has been used to treat hyperkinesias in Huntington's disease (HD). The aim of this study is to define the role of AP on chorea, motor performance, and functional disability, and to compare the effects of AP vs. TBZ in a small study of six patients with HD. Both AP and TBZ increased the Unified Huntington's Disease Rating Scale (UHDRS) chorea score in a similar way. However, AP caused less sedation and sleepiness than TBZ and was better tolerated by the patients on the trial. Moreover, AP showed a slight but not significant improvement of depression in the patients as compared to TBZ. A larger group of patients and a longer period of observation are an important prerequisite for further evaluations of AP's therapeutic use. © 2008 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn3"><p>Potential conflict of interest: None reported.</p></note><note xml:id="fn5"><p>Dr. Brusa and Dr. Orlacchio contributed equally to this work.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Treatment of the symptoms of Huntington's disease: Preliminary results comparing aripiprazole and tetrabenazine</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Treatment of HD with AP or TBZ</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Treatment of the symptoms of Huntington's disease: Preliminary results comparing aripiprazole and tetrabenazine</title></titleInfo><name type="personal"><namePart type="given">Livia</namePart><namePart type="family">Brusa</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>UOC Neurologia, Ospedale Sant'Eugenio, Rome, Italy</affiliation><description>Dr. Brusa and Dr. Orlacchio contributed equally to this work.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Antonio</namePart><namePart type="family">Orlacchio</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Laboratorio di Neurogenetica, CERC‐IRCCS Santa Lucia, Rome, Italy</affiliation><affiliation>Dipartimento di Neuroscienze, Università di Roma “Tor Vergata”, Rome, Italy</affiliation><description>Dr. Brusa and Dr. Orlacchio contributed equally to this work.</description><description>Correspondence: Laboratorio di Neurogenetica, Centro Europeo di Ricerca sul Cervello (CERC), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Santa Lucia, 64 Via del Fosso di Fiorano, Rome 00143, Italy</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Vincenzo</namePart><namePart type="family">Moschella</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Dipartimento di Neuroscienze, Università di Roma “Tor Vergata”, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Cesare</namePart><namePart type="family">Iani</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>UOC Neurologia, Ospedale Sant'Eugenio, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Giorgio</namePart><namePart type="family">Bernardi</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Laboratorio di Neurogenetica, CERC‐IRCCS Santa Lucia, Rome, Italy</affiliation><affiliation>Dipartimento di Neuroscienze, Università di Roma “Tor Vergata”, Rome, Italy</affiliation><affiliation>Laboratorio di Neurologia Sperimentale, CERC‐IRCCS Santa Lucia, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Nicola Biagio</namePart><namePart type="family">Mercuri</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Dipartimento di Neuroscienze, Università di Roma “Tor Vergata”, Rome, Italy</affiliation><affiliation>Laboratorio di Neurologia Sperimentale, CERC‐IRCCS Santa Lucia, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2009-01-15</dateIssued><dateCaptured encoding="w3cdtf">2008-04-20</dateCaptured><dateValid encoding="w3cdtf">2008-10-09</dateValid><copyrightDate encoding="w3cdtf">2009</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">1</extent><extent unit="references">15</extent><extent unit="words">2131</extent></physicalDescription><abstract lang="en">Aripiprazole (AP), a dopamine (DA) D2 receptor partial agonist, has recently been used to reduce schizophrenic symptoms, while tetrabenazine (TBZ), a DA depletor, has been used to treat hyperkinesias in Huntington's disease (HD). The aim of this study is to define the role of AP on chorea, motor performance, and functional disability, and to compare the effects of AP vs. TBZ in a small study of six patients with HD. Both AP and TBZ increased the Unified Huntington's Disease Rating Scale (UHDRS) chorea score in a similar way. However, AP caused less sedation and sleepiness than TBZ and was better tolerated by the patients on the trial. Moreover, AP showed a slight but not significant improvement of depression in the patients as compared to TBZ. A larger group of patients and a longer period of observation are an important prerequisite for further evaluations of AP's therapeutic use. © 2008 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: None reported.</note><note type="funding">Italian Ministry of Health - No. EBRI1.O; No. PS05.11; No. PS05.21; No. REG.13M; No. RF06.70M; </note><note type="funding">Comitato Telethon Fondazione Onlus</note><note type="funding">Amministrazione Autonoma dei Monopoli di Stato (AAMS)</note><note type="funding">Italian city of Gubbio - No. GGP06209; </note><subject lang="en"><genre>Keywords</genre><topic>Huntington's disease</topic><topic>aripiprazole</topic><topic>tetrabenazine</topic><topic>neuroleptics</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>126</start><end>129</end><total>4</total></extent></part></relatedItem><identifier type="istex">A4EAA2B1C46701DE647AB267806AF6E63F520792</identifier><identifier type="DOI">10.1002/mds.22376</identifier><identifier type="ArticleID">MDS22376</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2008 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D82 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002D82 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:A4EAA2B1C46701DE647AB267806AF6E63F520792
|texte= Treatment of the symptoms of Huntington's disease: Preliminary results comparing aripiprazole and tetrabenazine
}}
| This area was generated with Dilib version V0.6.23. |  |